STOCK TITAN

NeoGenomics (NASDAQ: NEO) director sells 5,307 shares in Form 4

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

NeoGenomics director Lynn A. Tetrault reported an open-market sale of 5,307 shares of Common Stock at $11.10 per share on June 15, 2026. After this transaction, she directly holds 86,115 Common shares.

She also indirectly holds 7,000 Common shares through a Lynn Tetrault Rollover IRA. In addition, she has 15,970 Restricted Stock Units tied to Common Stock and multiple stock option grants covering various numbers of underlying shares with exercise prices ranging from $8.10 to $41.76 and expirations between 2026 and 2036.

Positive

  • None.

Negative

  • None.
Insider TETRAULT LYNN A.
Role null
Sold 5,307 shs ($59K)
Type Security Shares Price Value
Sale Common Stock 5,307 $11.10 $59K
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Unit -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 86,115 shares (Direct, null); Stock Option (Right to Buy) — 2,136 shares (Direct, null); Restricted Stock Unit — 15,970 shares (Direct, null); Common Stock — 7,000 shares (Indirect, Lynn Tetrault Rollover IRA)
Footnotes (1)
  1. [object Object]
Shares sold 5,307 shares Open-market or private sale of Common Stock on June 15, 2026
Sale price $11.10 per share Price received for 5,307 Common shares sold
Direct holdings after sale 86,115 shares Common Stock directly owned following the June 15, 2026 sale
Indirect IRA holdings 7,000 shares Common Stock held via Lynn Tetrault Rollover IRA
Restricted Stock Units 15,970 units RSUs tied to Common Stock; once vested, not subject to expiration
Option exercise price $7.28 per share Stock option on 16,107 underlying Common shares, expiring June 1, 2035
Highest option exercise price $41.76 per share Stock option on 972 underlying Common shares, expiring October 11, 2028
Earliest option expiration June 6, 2026 Stock option on 2,136 underlying Common shares at $22.52 exercise price
Restricted Stock Unit financial
"The security title is listed as "Restricted Stock Unit" with underlying Common Stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"Multiple entries show "Stock Option (Right to Buy)" with specified exercise prices."
open-market sale financial
"The transaction_action field describes the event as an "open-market sale"."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"A Common Stock holding is marked with ownership_type "indirect" via a Rollover IRA."
Rollover IRA financial
"Nature of ownership notes "Lynn Tetrault Rollover IRA" for 7,000 shares."
exercise price financial
"Each stock option record includes a "conversion_or_exercise_price" field."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
TETRAULT LYNN A.

(Last)(First)(Middle)
9490 NEOGENOMICS WAY

(Street)
FORT MYERS FLORIDA 33912

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026S5,307D$11.186,115D
Common Stock7,000ILynn Tetrault Rollover IRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$22.5206/06/202006/06/2026Common Stock2,1362,136D
Stock Option (Right to Buy)$28.5405/28/202105/28/2027Common Stock3,4483,448D
Stock Option (Right to Buy)$40.906/02/202206/02/2028Common Stock3,7143,714D
Stock Option (Right to Buy)$41.7610/11/202210/11/2028Common Stock972972D
Stock Option (Right to Buy)$8.106/10/202306/10/2029Common Stock13,88213,882D
Stock Option (Right to Buy)$14.8208/10/202408/10/2033Common Stock8,3538,353D
Stock Option (Right to Buy)$13.7106/01/202506/01/2034Common Stock8,6728,672D
Stock Option (Right to Buy)$7.2806/01/202606/01/2035Common Stock16,10716,107D
Stock Option (Right to Buy)$10.5206/01/202706/01/2036Common Stock11,06911,069D
Restricted Stock Unit$006/01/2027 (1)Common Stock15,97015,970D
Explanation of Responses:
1. Once vested, the shares of common stock are not subject to expiration.
Remarks:
/s/ Ali Olivo, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many NeoGenomics (NEO) shares did Lynn A. Tetrault sell?

Lynn A. Tetrault sold 5,307 shares of NeoGenomics Common Stock. The sale was reported as an open-market or private transaction at a price of $11.10 per share on June 15, 2026.

What price did the NeoGenomics (NEO) director receive per share in this Form 4?

The reported sale price was $11.10 per share for 5,307 shares. This transaction involved Common Stock and was classified as an open-market sale or private transaction on June 15, 2026, according to the Form 4 data.

How many NeoGenomics (NEO) shares does Lynn A. Tetrault hold after the sale?

After the sale, Lynn A. Tetrault directly holds 86,115 shares of NeoGenomics Common Stock. She also indirectly holds 7,000 additional Common shares through a Lynn Tetrault Rollover IRA, as disclosed in the Form 4 ownership details.

What equity awards and options does the NeoGenomics (NEO) director still have?

She holds 15,970 Restricted Stock Units tied to NeoGenomics Common Stock and multiple stock options. These options cover various underlying share amounts with exercise prices between $8.10 and $41.76 and expiration dates ranging from 2026 through 2036.

Is the NeoGenomics (NEO) Form 4 sale by Lynn A. Tetrault a buy or sell transaction?

The Form 4 shows a sell transaction. It reports an open-market or private sale of 5,307 shares of NeoGenomics Common Stock, coded as a sale transaction, with no corresponding purchase or option exercise reported in this filing.